Company intelligence / Profile preview

Hauul Bio

South Korea

Ownership: Private
Development stage: Other

Overview

Hauul Bio has developed the ShotCAR and ModCAR platforms for non-viral universal CAR cell therapy. Programs targeting solid tumors and hematologic neoplasms are in preclinical development. No reported clinical trial results to date

Therapeutic areas: OncologyHematology
Modalities: AntibodyMonoclonal antibodyCAR-T cell therapyGene therapy
Industry: Biotech

Drug pipeline

23 assets

ShotCAR

Preclinical

22 more assets in the full pipeline.

Request access →

Partnerships

Collaborations claimed with industry, academia, research centers, and hospitals; specifics not listed

Beyond the preview

Go deeper on Hauul Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hauul Bio.

Explore the full profile